Studies have shown that after imatinib treatment with the GIST 882 cell line, imatinib induces BIM transcription, while the mitogen-Activated Protein Kinase (MAPK) signaling pathway reduces the ubiquitination and phosphorylation levels of BIM through post-translational levels. The gene discussed is BCL2L11; the disease is gastrointestinal stromal tumor.